BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …

A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Abstract Background Angiopoietin-like 3 (ANGPTL3) inhibits lipoprotein and endothelial
lipases and hepatic uptake of triglyceride-rich lipoprotein remnants. ANGPTL3 loss-of …

Background Inflammation and hyperlipidaemia jointly contribute to atherothrombotic
disease. However, when people are treated with intensive statin therapy, the relative …

BACKGROUND Reducing the levels of triglycerides and triglyceride-rich lipoproteins
remains an unmet clinical need. Olezarsen is an antisense oligonucleotide targeting …

Elevated triglycerides and non-high-density lipoprotein cholesterol (HDL-C) are risk factors
for atherosclerotic cardiovascular disease (ASCVD). ARO-ANG3 is an RNA interference …

Aims Cholesterol carried in triglyceride-rich lipoproteins, also called remnant cholesterol, is
being increasingly acknowledged as an important causal risk factor for atherosclerosis …

Pegozafermin, a long-acting glycopegylated analog of human fibroblast growth factor 21, is
in development for the treatment of severe hypertriglyceridemia (SHTG) and nonalcoholic …

Cardiovascular disease is the leading cause of death in women and men globally, with most
due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 …